Kirt Poss is an Executive Partner with Edgewater Capital Partners and a Fellow at the NobleReach Foundation. Previously, Kirt served as CEO-US of ProtaGene, a leading provider of advanced analytics in biopharmaceutical and gene therapy platform development, which was formed in a PE-backed merger in 2021.
Earlier, Kirt founded and served as President and CEO of BioAnalytix, where he led the company from early commercial growth through M&A with Protagen Protein Services in 2019. Before founding BioAnalytix, Mr. Poss co-founded and ran the biomarker imaging company VisEn Medical as President and CEO from its early technology platform formation through product development, pharmaceutical and clinical partnerships, worldwide commercialization and M&A with PerkinElmer in 2010. Earlier in his career, Mr. Poss worked in healthcare business strategy consulting with Kendall Strategies in Cambridge, MA, where he focused on commercial growth and M&A strategies in the pharmaceutical and medical device sectors. Before that he worked in scientific research at the Center for Molecular Imaging Research at the Massachusetts General Hospital and Harvard Medical School. He is a co-author of several scientific publications and multiple patents in biomarker imaging and pharmaceutical development. Mr. Poss earned a BA in Political Science and English from the University of Connecticut.
